Geneos Wealth Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-400
Closed -$7.42K 2203
2023
Q3
$7.42K Hold
400
﹤0.01% 1642
2023
Q2
$4.42K Hold
400
﹤0.01% 1769
2023
Q1
$5.37K Hold
400
﹤0.01% 1705
2022
Q4
$4.95K Hold
400
﹤0.01% 1704
2022
Q3
$5K Hold
400
﹤0.01% 1713
2022
Q2
$5K Hold
400
﹤0.01% 2223
2022
Q1
$6K Hold
400
﹤0.01% 2305
2021
Q4
$6K Hold
400
﹤0.01% 2384
2021
Q3
$6K Hold
400
﹤0.01% 2421
2021
Q2
$7K Hold
400
﹤0.01% 2356
2021
Q1
$7K Hold
400
﹤0.01% 2563
2020
Q4
$9K Hold
400
﹤0.01% 2278
2020
Q3
$16K Hold
400
﹤0.01% 1775
2020
Q2
$30K Hold
400
﹤0.01% 1446
2020
Q1
$26K Hold
400
﹤0.01% 1407
2019
Q4
$49K Hold
400
﹤0.01% 1275
2019
Q3
$25K Hold
400
﹤0.01% 1518
2019
Q2
$31K Hold
400
﹤0.01% 1426
2019
Q1
$44K Sell
400
-200
-33% -$21.9K ﹤0.01% 1213
2018
Q4
$56K Buy
600
+100
+20% +$10.4K ﹤0.01% 1043
2018
Q3
$63K Buy
500
+100
+25% +$10.6K ﹤0.01% 1064
2018
Q2
$33K Hold
400
﹤0.01% 1246
2018
Q1
$24K Hold
400
﹤0.01% 1322
2017
Q4
$23K Hold
400
﹤0.01% 1336
2017
Q3
$23K Buy
+400
New +$43.1K ﹤0.01% 1274

Geneos Wealth Management's ICPT Position: Q4 2023 in Review

Geneos Wealth Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 400 shares — an estimated $7.42K sold.

Geneos Wealth Management first reported a position in ICPT in Q3 2017 and held it in 25 quarters. The position peaked at $63K in Q3 2018. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

  • Geneos Wealth Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Geneos Wealth Management sold 400 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $7.42K.
  • Geneos Wealth Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2017 and held it in 25 quarters.
  • Geneos Wealth Management's Intercept Pharmaceuticals, Inc. position peaked at $63K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Geneos Wealth Management's 13F filing for Q4 2023, filed 26 Jan 2024.